AFLIBERCEPT | B761355 | REGENERON PHARMACEUTICALS
Regulatory Exclusivities
| Type | Expiry | Status | Source |
|---|---|---|---|
| 12-Year BPCIA | Aug. 18, 2035 | Active | Computed |
Purple Book Patents
No listed patents in Purple Book.
Estimated Patent LOE
Based on latest discovered patent 12338274(formulation) · relevance 92/100
Estimate based on AI-discovered patents. No patents are officially listed in the Purple Book for this product.
0 AI-discovered patents, sorted by relevance.
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Buchanan Ingersoll & Rooney PC FDA-2026-P-2257 Buchanan Ingersoll & Rooney PC filed this citizen petition on behalf of an unnamed interested client under Federal Food, Drug, and Cosmetic Act sections 501(a)(2)(A), 502(a), 502(f), 503B, and 704, requesting that the FDA issue guidance clarifying that compounded ophthalmic bevacizumab products do n | Other | 2026-03-04 | Withdrawn | Buchanan Ingersoll & Rooney PC |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.